Safety and immunogenicity of a pneumococcal histidine triad protein D vaccine candidate in adults

Vaccine

Volumn 30, Issue 52, 2012, Pages 7455-7460

  Seiberling, Michael ^a   Bologa, Monica ^b   Brookes, Roger ^b   Ochs, Martina ^b   Go, Kerry ^c   Neveu, David ^c   Kamtchoua, Thierry ^a   Lashley, Peter ^b   Yuan, Tao ^b   Gurunathan, Sanjay ^c  

^a Covance Clinical Research Unit AG ^*  (Switzerland)

^b Sanofi Pasteur   (Canada)

^c SANOFI PASTEUR   (France)

Author keywords

Adults; Clinical trial; Immunogenicity; Pneumococcal histidine triad protein D; Protein vaccine; Safety

Indexed keywords

BACTERIAL PROTEIN; BACTERIUM ANTIBODY; PNEUMOCOCCUS VACCINE; RECOMBINANT HISTIDINE TRIAD PROTEIN D; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ADULT; ANTIBODY RESPONSE; ARTICLE; COHORT ANALYSIS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALAISE; MYALGIA; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PILOT STUDY; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; SINGLE DRUG DOSE; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; DRUG TOXICITY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYDROLASES; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; PNEUMOCOCCAL VACCINES; RECOMBINANT PROTEINS; STREPTOCOCCUS PNEUMONIAE; VACCINATION; VACCINES, SYNTHETIC; YOUNG ADULT;

EID: 84870540492     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.10.080     Document Type: Article

References (26)

1. O'Brien K.L., Wolfson L.J., Watt J.P., Henkle E., Deloria-Knoll M., McCall N., et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009, 374:893-902.
2. Hausdorff W.P., Bryant J., Kloek C., Paradiso P.R., Siber G.R. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. Clin Infect Dis 2000, 30:122-140.
3. Black S., Eskola J., Whitney C., Shienfeld H. Pneumococcal conjugate vaccine and pneumococcal common protein vaccines. Vaccines 2008, 531-567. Saunders Elsevier, Amsterdam. fifth edition. S. Plotkin, W. Orenstein, P. Offit (Eds.).
4. Temple K., Greenwood B., Inskip H., Hall A., Koskela M., Leinonen M. Antibody response to pneumococcal capsular polysaccharide vaccine in African children. Pediatr Infect Dis J 1991, 10:386-390.
5. Lynch J.P., Zhanel G.G. Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention. Semin Respir Crit Care Med 2009, 30:189-209.
6. Rozenbaum M.H., Boersma C., Postma M.J., Hak E. Observed differences in invasive pneumococcal disease epidemiology after routine infant vaccination. Expert Rev Vaccines 2011, 10:187-199.
7. Domínguez A., Ciruela P., Garcia-Garcia J.J., Moraga F., Sevilla M.F., Selva L., et al. Effectiveness of 7-valent pneumococcal conjugate vaccine in the prevention of invasive pneumococcal disease in children aged 7-59 months. A matched case-control study. Vaccine 2011, 29:9020-9025.
8. Miller E., Andrews N.J., Waight P.A., Slack M.P., George R.C. Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine. Vaccine 2011, 29:9127-9131.
9. Whitney C.G., Pilishvili T., Farley M.M., Schaffner W., Craig A.S., Lynfield R., et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006, 368:1495-1502.
10. van den Bergh M.R., Spijkerman J., Francois N., Swinnen K., Borys D., Schuerman L., et al. Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine and DTPa-IPV-Hib when coadministered as a 3-dose primary vaccination schedule in The Netherlands: a randomized controlled trial. Pediatr Infect Dis J 2011, 30:e170-e178.
11. Mera R., Miller L.A., Fritsche T.R., Jones R.N. Serotype replacement and multiple resistance in Streptococcus pneumoniae after the introduction of the conjugate pneumococcal vaccine. Microb Drug Resist 2008, 14:101-107.
12. Weinberger D.M., Malley R., Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet 2011, 378:1962-1973.
13. McIntosh E.D., Reinert R.R. Global prevailing and emerging pediatric pneumococcal serotypes. Expert Rev vaccines 2011, 10:109-129.
14. Paton J.C., Boslego J.W. Protein vaccines. Pneumococcal vaccines: the impact of conjugate vaccine 2008, 421-436. ASM Press, Washington, DC. G.R. Siber, K.P. Klugman, P.H. Makela (Eds.).
15. Adamou J.E., Heinrichs J.H., Erwin A.L., Walsh W., Gayle T., Dormitzer M., et al. Identification and characterization of a novel family of pneumococcal proteins that are protective against sepsis. Infect Immun 2001, 69:949-958.
16. Hava D.L., Camilli A. Large-scale identification of serotype 4 Streptococcus pneumoniae virulence factors. Mol Microbiol 2002, 45:1389-1406.
17. Beghetto E., Gargano N., Ricci S., Garufi G., Peppoloni S., Montagnani F., et al. Discovery of novel Streptococcus pneumoniae antigens by screening a whole-genome lambda-display library. FEMS Microbiol Lett 2006, 262:14-21.
18. Hagerman A., Posfay-Barbe K.M., Grillet S., Ochs M.M., Brookes R.H., Greenberg D., et al. Failure to elicit seroresponses to pneumococcal surface proteins (pneumococcal histidine triad D, pneumococcal choline-binding protein A, and serine proteinase precursor A) in children with pneumococcal bacteraemia. Clin Microbiol Infect 2012, 18(8):756-762.
19. Kaur R., Casey J.R., Pichichero M.E. Serum antibody response to five Streptococcus pneumoniae proteins during acute otitis media in otitis-prone and non-otitis-prone children. Pediatr Infect Dis J 2011, 30:645-650.
20. Holmlund E., Quiambao B., Ollgren J., Jaakkola T., Neyt C., Poolman J., et al. Antibodies to pneumococcal proteins PhtD, CbpA, and LytC in Filipino pregnant women and their infants in relation to pneumococcal carriage. Clin Vaccine Immunol 2009, 16:916-923.
21. Denoel P., Philipp M.T., Doyle L., Martin D., Carletti G., Poolman J.T. A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae. Vaccine 2011, 29:5495-5501.
22. Ljutic B., Ochs M., Messham B., Ming M., Dookie A., Harper K., et al. Formulation, stability and immunogenicity of a trivalent pneumococcal protein vaccine formulated with aluminum salt adjuvants. Vaccine 2012, 30:2981-2988.
23. Collett D. Modelling binary data 2002, Chapman & Hall/CRC, Boca Raton, FL. 2nd edition.
24. Lindblad E.B. Aluminium compounds for use in vaccines. Immunol Cell Biol 2004, 82:497-505.
25. Lode H., Schmoele-Thoma B., Gruber W., Ahlers N., Fernsten P., Baker S., et al. Dose-ranging study of a single injection of pneumococcal conjugate vaccine (1×, 2×, or 4×) in healthy subjects aged 70 years or older. Vaccine 2011, 29:4940-4946.
26. Rodgers G.L., Klugman K.P. The future of pneumococcal disease prevention. Vaccine 2011, 29(Suppl. 3):C43-C48.